Provenance Record

Clean, well-structured Briefing (465 words, within the 300-800 range). Overview / What We Know / The Company / What We Don't Know structure is appropriate for a company-announcement story. Every paragraph carries an inline attribution link, and the framing is careful to attribute claims to the company and to the FDA-as-quoted-in-the-announcement rather than asserting them as independently established fact.

Both source snapshots read from disk (both fetched at HTTP 200; the FDA.gov page was NOT bot-blocked for the chief:review fetcher in this run). source-0.html.gz (BioSpace / ACCESS Newswire press release, July 7 2026) — CONFIRMED every inline claim: 'first AI-driven Drug Development Tool accepted into the FDA's ISTAND qualification pathway'; Digital Liver Model for predicting DILI; Letter of Intent stage of the FDA's three-stage ISTAND DDT Qualification Program; Boston biotech founded 2024; co-founders Farhan Khodaee PhD (CEO), Rohola Zandie PhD (CTO), Robert Betancort MBA (COO); Digital Liver Model is the first application of the company's broader AI platform; the FDA-attributed DILI quote ('one of the most significant safety concerns... yet current modeling does not accurately identify DILI risk in humans') appears verbatim; the prediction-gap sentence (metabolism, genetics, immune response, dose and exposure history) is supported; the 'addresses these complexities by combining mechanistic biology with AI trained on drug-response data...' quote is verbatim; the NAMs / 'new category of AI-based DDTs and New Approach Methodologies (NAMs)... reduce reliance on animal testing' framing is verbatim; both Khodaee quotes are verbatim. source-1.html.gz (FDA.gov Drug Alerts and Statements) — listed in sources as the primary reference; snapshot succeeded and independently corroborates the acceptance, LOI, ISTAND, DILI, DDT and NAM framing. All inline body claims rest on the BioSpace snapshot as intended.

No hallucinations detected. All direct quotes match the BioSpace snapshot verbatim. The DILI quote is honestly attributed as 'According to the FDA, as quoted in the announcement' / 'per BioSpace' — which is exactly how BioSpace presents it. FDA-statement-only specifics that the Journalist deliberately excluded ('in silico', 'CDER', the '3Rs', small-molecule scope, phase I, chemical-structure comparison, weight-of-evidence, and the named later qualification stages, plus FDA officials Michael Davis and Jeffrey Siegel) were confirmed ABSENT from the article body via keyword scan — none leaked in. The 'not yet a fully qualified FDA drug-development tool' characterization is a fair inference from LOI being the first of three stages and is flagged appropriately in the What We Don't Know section.

APPROVE. A clean, well-attributed Briefing. Both sources are on the allowlist (biospace.com, fda.gov). Every specific, quote and 'first'/DILI/Letter-of-Intent claim traces to the BioSpace snapshot, and the FDA snapshot independently corroborates the core facts. The Journalist correctly confined FDA-statement-only specifics out of the body. No corrections needed.